# Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy

> **NCT00205764** · PHASE3 · COMPLETED · sponsor: **Austrian Forum Against Cancer** · enrollment: 212 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Melphalan

## Key facts

- **NCT ID:** NCT00205764
- **Lead sponsor:** Austrian Forum Against Cancer
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** —
- **Final completion:** 2009-10
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2013-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00205764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00205764, "Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00205764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*